Vor Biopharma Inc. (VOR)
- Previous Close
1.8800 - Open
1.8600 - Bid 1.7000 x 100
- Ask 1.7600 x 300
- Day's Range
1.7300 - 1.8600 - 52 Week Range
1.6200 - 5.7000 - Volume
286,825 - Avg. Volume
325,850 - Market Cap (intraday)
118.695M - Beta (5Y Monthly) -0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7500 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.69
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
www.vorbio.comRecent News: VOR
Performance Overview: VOR
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VOR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VOR
Valuation Measures
Market Cap
118.70M
Enterprise Value
17.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.79
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.67%
Return on Equity (ttm)
-58.74%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-117.86M
Diluted EPS (ttm)
-1.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
137.18M
Total Debt/Equity (mrq)
23.66%
Levered Free Cash Flow (ttm)
-58.02M